Literature DB >> 24500761

Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.

Ales Vicha1, David Taieb, Karel Pacak.   

Abstract

Warburg's metabolic hypothesis is based on the assumption that a cancer cell's respiration must be under attack, leading to its damage, in order to obtain increased glycolysis. Although this may not apply to all cancers, there is some evidence proving that primarily abnormally functioning mitochondrial complexes are indeed related to cancer development. Thus, mutations in complex II (succinate dehydrogenase (SDH)) lead to the formation of pheochromocytoma (PHEO)/paraganglioma (PGL). Mutations in one of the SDH genes (SDHx mutations) lead to succinate accumulation associated with very low fumarate levels, increased glutaminolysis, the generation of reactive oxygen species, and pseudohypoxia. This results in significant changes in signaling pathways (many of them dependent on the stabilization of hypoxia-inducible factor), including oxidative phosphorylation, glycolysis, specific expression profiles, as well as genomic instability and increased mutability resulting in tumor development. Although there is currently no very effective therapy for SDHx-related metastatic PHEOs/PGLs, targeting their fundamental metabolic abnormalities may provide a unique opportunity for the development of novel and more effective forms of therapy for these tumors.

Entities:  

Keywords:  SDHx; Warburg effect; gastrointestinal stromal tumor; glycolysis; hypoxia; paraganglioma; pheochromocytoma; pseudohypoxia; reactive oxygen species; renal cell carcinoma; succinate dehydrogenase

Mesh:

Substances:

Year:  2014        PMID: 24500761      PMCID: PMC4016161          DOI: 10.1530/ERC-13-0398

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  211 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1.

Authors:  Kohei Matsushita; Keiichi Uchida; Susumu Saigusa; Shozo Ide; Kiyoshi Hashimoto; Yuki Koike; Kohei Otake; Mikihiro Inoue; Koji Tanaka; Masato Kusunoki
Journal:  J Pediatr Surg       Date:  2012-07       Impact factor: 2.545

3.  Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells.

Authors:  Barbara Chiavarina; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Anthony Howell; Herbert B Tanowitz; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

4.  Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells.

Authors:  Meng Meng; Shuyang Chen; Taotao Lao; Dongming Liang; Nianli Sang
Journal:  Cell Cycle       Date:  2010-10-25       Impact factor: 4.534

5.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.

Authors:  Andrew Y Choo; Sang Gyun Kim; Matthew G Vander Heiden; Sarah J Mahoney; Hieu Vu; Sang-Oh Yoon; Lewis C Cantley; John Blenis
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

Review 6.  Genomic imprinting and environment in hereditary paraganglioma.

Authors:  Bora E Baysal
Journal:  Am J Med Genet C Semin Med Genet       Date:  2004-08-15       Impact factor: 3.908

7.  Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis.

Authors:  Robert D Guzy; Bhumika Sharma; Eric Bell; Navdeep S Chandel; Paul T Schumacker
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

8.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.

Authors:  David Lando; Daniel J Peet; Jeffrey J Gorman; Dean A Whelan; Murray L Whitelaw; Richard K Bruick
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

9.  Opposite effects of HIF-1α and HIF-2α on the regulation of IL-8 expression in endothelial cells.

Authors:  Urszula Florczyk; Szymon Czauderna; Anna Stachurska; Magdalena Tertil; Witold Nowak; Magdalena Kozakowska; Lorenz Poellinger; Alicja Jozkowicz; Agnieszka Loboda; Jozef Dulak
Journal:  Free Radic Biol Med       Date:  2011-08-30       Impact factor: 7.376

10.  Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success.

Authors:  Cristina Branco-Price; Na Zhang; Moritz Schnelle; Colin Evans; Dörthe M Katschinski; Debbie Liao; Lesley Ellies; Randall S Johnson
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

View more
  16 in total

1.  Absence of BRAF mutation in pheochromocytoma and paraganglioma.

Authors:  T Vosecka; A Vicha; T Zelinka; P Jencova; K Pacak; J Duskova; J Benes; A Guha; L Stanek; M Kohoutova; Z Musil
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

2.  Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas.

Authors:  Dominique Barbolosi; Sebastien Hapdey; Stephanie Battini; Christian Faivre; Julien Mancini; Karel Pacak; Bardia Farman-Ara; David Taïeb
Journal:  Med Biol Eng Comput       Date:  2015-06-05       Impact factor: 2.602

Review 3.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

4.  Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells.

Authors:  Stephanie Mj Fliedner; Chunzhang Yang; Eli Thompson; Mones Abu-Asab; Chang-Mei Hsu; Gary Lampert; Lee Eiden; Arthur S Tischler; Robert Wesley; Zhengping Zhuang; Hendrik Lehnert; Karel Pacak
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 5.  Pheochromocytoma: Gasping for Air.

Authors:  Ivana Jochmanová; Zhengping Zhuang; Karel Pacak
Journal:  Horm Cancer       Date:  2015-07-03       Impact factor: 3.869

6.  Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics.

Authors:  Arthur Varoquaux; Yann le Fur; Alessio Imperiale; Antony Reyre; Marion Montava; Nicolas Fakhry; Izzie-Jacques Namer; Guy Moulin; Karel Pacak; Maxime Guye; David Taïeb
Journal:  Endocr Relat Cancer       Date:  2015-06-26       Impact factor: 5.678

7.  Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma.

Authors:  Ying Pang; Yanxin Lu; Veronika Caisova; Yang Liu; Petra Bullova; Thanh-Truc Huynh; Yiqiang Zhou; Di Yu; Zdenek Frysak; Igor Hartmann; David Taïeb; Karel Pacak; Chunzhang Yang
Journal:  Clin Cancer Res       Date:  2018-04-10       Impact factor: 12.531

8.  Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.

Authors:  Alessio Imperiale; François-Marie Moussallieh; Philippe Roche; Stéphanie Battini; A Ercument Cicek; Frédéric Sebag; Laurent Brunaud; Anne Barlier; Karim Elbayed; Anderson Loundou; Philippe Bachellier; Bernard Goichot; Constantine A Stratakis; Karel Pacak; Izzie-Jacques Namer; David Taïeb
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

9.  Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models.

Authors:  Petra Bullova; Antony Cougnoux; Luma Abunimer; Juraj Kopacek; Silvia Pastorekova; Karel Pacak
Journal:  Oncotarget       Date:  2016-06-28

Review 10.  Heritable Cancer Syndromes Related to the Hypoxia Pathway.

Authors:  John Clark Henegan; Christian R Gomez
Journal:  Front Oncol       Date:  2016-03-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.